Standout Papers

Immune-related adverse events and anti-tumor efficacy... 2013 2026 2017 2021 745
  1. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019)
    Satya Das, Douglas B. Johnson Journal for ImmunoTherapy of Cancer
  2. Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy (2013)
    Hubing Shi, Willy Hugo et al. Cancer Discovery
  3. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab (2016)
    Alexander M. Menzies, Douglas B. Johnson et al. Annals of Oncology
  4. Immune-checkpoint inhibitors: long-term implications of toxicity (2022)
    Douglas B. Johnson, Caroline A. Nebhan et al. Nature Reviews Clinical Oncology
  5. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy (2019)
    Daniel Shae, Kyle W. Becker et al. Nature Nanotechnology
  6. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance (2015)
    Willy Hugo, Hubing Shi et al. Cell
  7. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade (2019)
    Steve Lu, Julie E. Stein et al. JAMA Oncology
  8. Cardiovascular toxicities associated with immune checkpoint inhibitors (2019)
    Jiun‐Ruey Hu, Roberta Florido et al. Cardiovascular Research
  9. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study (2019)
    Douglas B. Johnson, Ali Manouchehri et al. Journal for ImmunoTherapy of Cancer
  10. Endocrine toxicities of immune checkpoint inhibitors (2021)
    J. J. Wright, Alvin C. Powers et al. Nature Reviews Endocrinology

Immediate Impact

5 by Nobel laureates 8 from Science/Nature 92 standout
Sub-graph 1 of 18

Citing Papers

Pyridinium Rotor Strategy toward a Robust Photothermal Agent for STING Activation and Multimodal Image-Guided Immunotherapy for Triple-Negative Breast Cancer
2025 Standout
A vision–language foundation model for precision oncology
2025 StandoutNature
11 intermediate papers

Works of Douglas B. Johnson being referenced

Immune-checkpoint inhibitors: long-term implications of toxicity
2022 Standout
Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma
2020
and 6 more

Author Peers

Author Last Decade Papers Cites
Douglas B. Johnson 9445 4462 3922 289 13.5k
Ryan J. Sullivan 9244 3856 3239 381 12.9k
Alexander M. Menzies 9505 5005 3093 326 12.1k
Matteo S. Carlino 9269 4588 3616 299 12.0k
Igor Puzanov 10021 6732 3784 300 15.1k
Steven O’Day 9336 4675 4551 195 12.6k
Aurélien Marabelle 9849 2635 5586 272 14.5k
Michael A. Postow 11833 2801 5121 227 14.9k
Bart Neyns 9568 4159 4325 310 13.5k
Richard D. Carvajal 7072 4660 3774 284 12.0k
Harriet M. Kluger 7565 5046 3467 312 12.0k

All Works

Loading papers...

Rankless by CCL
2026